Immune subgroups and the tumor microenvironment as a potential new biomarker to assess response to immunotherapy

Immunotherapy has emerged as a new standard of care therapeutic option for patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma. Following the recent presentation of Keynote-048, the use of Pembrolizumab either as a single agent or in combination with chemotherapy can be considered as first-line treatment for patients with measurable PD-L1 in their tumor or microenvironment (1).